Ally Bridge Group’s Mersana Therapeutics MRSN Stock Holding History

Ally Bridge Group’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-32,057	Closed	-$3.59M	–	28
2024 Q1	$3.59M	Buy	+32,057	New	+$3.19M	2%	19
2023 Q2	–	Sell	-47,651	Closed	-$4.9M	–	20
2023 Q1	$4.9M	Hold	47,651	–	–	6.42%	8
2022 Q4	$6.98M	Buy	47,651 +10,389	+28%	+$1.76M	6.79%	4
2022 Q3	$6.3M	Buy	+37,262	New	+$6.06M	4.16%	10

Other funds holding MRSN

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ally Bridge Group's MRSN Position: Q2 2024 in Review

Ally Bridge Group sold out of Mersana Therapeutics (MRSN) in Q2 2024, closing a stake of 32,057 shares — an estimated $3.59M sold.

Ally Bridge Group first reported a position in MRSN in Q3 2022 and held it in 4 quarters. The position peaked at $6.98M in Q4 2022. 120 funds tracked by Wall St. Rank hold MRSN as of Q2 2024.

Ally Bridge Group reported no remaining Mersana Therapeutics position as of Q2 2024 after selling out during the quarter.
Ally Bridge Group sold 32,057 Mersana Therapeutics shares in Q2 2024, an estimated $3.59M.
Ally Bridge Group first reported a position in Mersana Therapeutics in Q3 2022 and held it in 4 quarters.
Ally Bridge Group's Mersana Therapeutics position peaked at $6.98M in Q4 2022.
120 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2024.

Based on Ally Bridge Group's 13F filing for Q2 2024, filed 14 Aug 2024.